The latest announcement is out from Septerna, Inc. ( (SEPN) ).

Septerna (SEPN) announced the dosing of the first participants in its Phase 1 clinical trial of SEP-631, a selective oral small molecule ...

(Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the dosing of the first participants in its Phase 1 ...

Septerna takes a different approach to the disease with SEP-786, a small molecule that targets and activates the parathyroid hormone 1 receptor (PTH1R), sparking it to produce more of the key hormone.

SOUTH SAN FRANCISCO, Calif., September 30, 2024--Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, presented new preclinical data from its ...

Reports Q3 revenue $176,000 vs $33,000 last year. "At Septerna (SEPN), we recently celebrated two major milestones: our transition to a clinical-stage company with the initiation of our Phase 1 ...

Septerna Inc has a consensus price target of $33 based on the ratings of 4 analysts. The high is $50 issued by Cantor Fitzgerald on February 11, 2025. The low is $11 issued by Wells Fargo on March ...

(Reuters) -Septerna's shares rose about 31% in their market debut on Friday, giving the Goldman Sachs-backed biotech firm a valuation of $970 million. The company's shares opened at $23.5 in their ...

We recently compiled a list of the 10 Stocks With At Least $30 Million In Insider Spending Recently. In this article, we are going to take a look at where Septerna, Inc. (NASDAQ:SEPN) stands ...

Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed.

Debt Management: Septerna's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.06. The Core of Analyst Ratings: What Every Investor Should Know ...

Septerna has science from a Nobel laureate and technology that finds new ways to drug GPCRs, well-validated receptors targeted by about one-third of FDA-approved medicines.